Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy.

Abstract

OBJECTIVES:

Clinicians often face the challenge of providing effective and safe therapy for pregnant women with uveitis. Certolizumab pegol (CZP) differs from other anti-TNFα agents due to its limited placental transfer. In this study we assessed the efficacy of CZP in pregnant women with uveitis. We also provided information on outcomes of pregnant women and neonates exposed to CZP.

METHODS:

We carried out a multicentre study of women with uveitis who received CZP during pregnancy and their neonates. The main visual outcomes were visual acuity (VA), intraocular inflammation and corticosteroid-sparing effect. Pregnancy outcomes, maternal and neonatal infections and congenital malformations were also assessed.

RESULTS:

We studied 14 women (23 affected eyes); mean age of 34.3±5.5 years. The underlying diseases were spondyloarthritis (n=7), idiopathic (n=2), and Vogt-Koyanagi-Harada, rheumatoid arthritis, juvenile idiopathic arthritis, punctate inner choroidopathy and Behçet's disease (1 each). The patterns of ocular involvement were anterior (n=10), posterior (n=2), intermediate (n=1), panuveitis (n=1). Cystoid macular oedema was present in one patient (1 eye). Uveitis was bilateral in nine cases and chronic in seven patients. CZP was started before getting pregnant in ten patients and after conceiving in four. All patients achieved or maintained ocular remission throughout pregnancy. Fifteen healthy infants were born. Only one woman presented a mild infection during pregnancy. Neither infections nor malformations were observed in neonates after a follow-up of 6 months. Six infants were breastfed and all of them received scheduled vaccinations without complications.

CONCLUSIONS:

Certolizumab pegol is effective and safe in women with uveitis during pregnancy.

• Authors: Diana Prieto-Peña, Mónica Calderón-Goercke, Alfredo Adán, Lillian Chamorro-López, Olga Maíz-Alonso, Juan R De Dios-Jiménez Aberásturi, Raúl Veroz, Soledad Blanco, José M Martín-Santos, Francisco Navarro, Adela Gallego, Senén González-Suárez, Arantxa Conesa, Andrea García-Valle, Miguel Cordero-Coma, Nieves Pardiñas-Barón, Rosalía Demetrio, Vanesa Calvo-Río, Víctor M Martínez-Taboada, Santos Castañeda, José L Hernández, Miguel A González-Gay, Ricardo Blanco
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) 2021 Jan-Feb Vol. 39 Issue 1 Pg. 105-114 ISSN: 0392-856X [Print] Italy
• PMID: 33124565 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Immunosuppressive Agents
• Certolizumab Pegol

Topics

• Adult
• Biological Therapy
• Certolizumab Pegol (adverse effects)
• Female
• Humans
• Immunosuppressive Agents (adverse effects)
• Infant
• Infant, Newborn
• Pregnancy
• Pregnant Women
• Treatment Outcome
• Uveitis (diagnosis, drug therapy)